Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RM-018 |
Synonyms | |
Therapy Description |
RM-018 covalently binds and inhibits GTP-bound KRAS G12C by forming a complex with the chaperone protein cyclophilin A, resulting in decreased downstream signaling and potentially inhibiting tumor growth (PMID: 33824136). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RM-018 | RM018|RM 018 | KRAS G12C inhibitor 36 | RM-018 covalently binds and inhibits GTP-bound KRAS G12C by forming a complex with the chaperone protein cyclophilin A, resulting in decreased downstream signaling and potentially inhibiting tumor growth (PMID: 33824136). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS G12C | Advanced Solid Tumor | sensitive | RM-018 | Preclinical - Cell culture | Actionable | In a preclinical study, RM-018 inhibited viability of cultured cells expressing NRAS G12C (PMID: 38236605). | 38236605 |
HRAS G12C | Advanced Solid Tumor | sensitive | RM-018 | Preclinical - Cell culture | Actionable | In a preclinical study, RM-018 inhibited viability of cultured cells expressing HRAS G12C (PMID: 38236605). | 38236605 |
BRAF V600E | melanoma | no benefit | RM-018 | Preclinical - Cell culture | Actionable | In a preclinical study, RM-018 did not inhibit growth of melanoma cells harboring BRAF V600E in culture (PMID: 33824136). | 33824136 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|